• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者是否有药物相关性颌骨坏死的生活质量。

Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.

机构信息

Postgraduate Program in Dentistry, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil.

Department of Oral and Maxillofacial Surgery, Erasto Gaertner Cancer Center, Curitiba, Paraná, Brazil.

出版信息

Support Care Cancer. 2021 Nov;29(11):6713-6719. doi: 10.1007/s00520-021-06275-w. Epub 2021 May 10.

DOI:10.1007/s00520-021-06275-w
PMID:33973080
Abstract

PURPOSE

Cancer and its therapies can have a significant impact on general and oral health and, therefore, cause a reduction in patients' quality of life (QoL). The study aimed to evaluate the QoL of cancer patients who use antiresorptive and anti-angiogenic medications with or without the development of medication-related osteonecrosis of the jaws (MRONJ).

METHODS

Sixty-two patients diagnosed with cancer under antiresorptive therapy answered three instruments from the European Organization for Cancer Research and Treatment (EORTC). The first questionnaire (QLQ-C30) aimed to measure the overall QoL, the second (QLQ-ELD14) is a complementary module for elderly patients, and the third (QLQ-OH15) aimed to assess oral health related to QoL.

RESULTS

The mean age of the patients was 62.19 years, and 12.9% developed MRONJ. There was no significant difference between sex and MRONJ. Among the QLQ-C30 scales, the item "role functioning (RF2)" presented a significant result (p = 0.019). Those patients without MRONJ had a better function performance both in their daily chores and in their free time. Age was not associated to MRONJ, although some concerns are common to the elderly and cancer patients. QoL related to oral health presented a significant result (p = 0.048) showing that MRONJ has a negative impact on patients' QoL.

CONCLUSION

Our results showed that MRONJ has a significant impact on the general and oral QoL of cancer patients, and therefore prevention and awareness must be a priority.

摘要

目的

癌症及其治疗方法会对整体健康和口腔健康产生重大影响,从而降低患者的生活质量(QoL)。本研究旨在评估使用抗吸收和抗血管生成药物的癌症患者的 QoL,无论是否发生药物相关性颌骨坏死(MRONJ)。

方法

62 名接受抗吸收治疗的癌症患者回答了欧洲癌症研究与治疗组织(EORTC)的三个问卷。第一个问卷(QLQ-C30)旨在测量整体 QoL,第二个(QLQ-ELD14)是专为老年患者设计的补充模块,第三个(QLQ-OH15)旨在评估与 QoL 相关的口腔健康。

结果

患者的平均年龄为 62.19 岁,12.9%发生了 MRONJ。性别与 MRONJ 之间无显著差异。在 QLQ-C30 量表中,“角色功能(RF2)”项目呈现显著结果(p=0.019)。无 MRONJ 的患者在日常家务和休闲时间的功能表现更好。年龄与 MRONJ 无关,但一些老年人和癌症患者共有的问题需要关注。与口腔健康相关的 QoL 呈现显著结果(p=0.048),表明 MRONJ 对患者的 QoL 有负面影响。

结论

我们的结果表明,MRONJ 对癌症患者的整体和口腔 QoL 有重大影响,因此预防和意识必须是优先事项。

相似文献

1
Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.癌症患者是否有药物相关性颌骨坏死的生活质量。
Support Care Cancer. 2021 Nov;29(11):6713-6719. doi: 10.1007/s00520-021-06275-w. Epub 2021 May 10.
2
Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.颌骨药物相关性骨坏死的患病率是否被低估:肿瘤及非肿瘤疾病中的评估
Bratisl Lek Listy. 2017;118(12):724-731. doi: 10.4149/BLL_2017_137.
3
Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw.患者的生活质量在接受 III 期药物相关性颌骨骨坏死的手术干预后得到改善。
Oral Maxillofac Surg. 2021 Sep;25(3):359-366. doi: 10.1007/s10006-020-00927-7. Epub 2020 Nov 23.
4
Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.药物相关性颌骨坏死与生活质量:综述与结构化分析
Br J Oral Maxillofac Surg. 2020 Jul;58(6):619-624. doi: 10.1016/j.bjoms.2020.03.010. Epub 2020 Apr 1.
5
Development and evaluation of the clinimetric properties of the Medication-Related Osteonecrosis of the Jaw Quality of Life Questionnaire (MRONJ-QoL).《药物相关性颌骨坏死生活质量问卷(MRONJ-QoL)的临床测量特性的制定与评估》。
Int J Oral Maxillofac Surg. 2022 Jun;51(6):768-775. doi: 10.1016/j.ijom.2021.11.007. Epub 2021 Dec 17.
6
Which symptoms negatively affect the oral health-related quality of life in patients with osteonecrosis of the jaw?哪些症状会对颌骨骨坏死患者的口腔健康相关生活质量产生负面影响?
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Aug;130(2):175-180. doi: 10.1016/j.oooo.2020.03.051. Epub 2020 May 31.
7
Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study.药物相关性颌骨坏死(MRONJ)与生活质量评估:一项初步研究。
Clin Ter. 2017 Jul-Aug;168(4):e253-e257. doi: 10.7417/T.2017.2015.
8
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.药物相关性颌骨坏死:纪念斯隆凯特琳癌症中心经验及预防中预防性牙科评估作用的最新进展
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):440-445. doi: 10.1016/j.oooo.2018.02.003. Epub 2018 Feb 14.
9
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
10
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.药物性颌骨坏死的发生率及其相关危险因素。
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9.

引用本文的文献

1
Bone-formation-related markers in osteonecrosis of the jaws and their correlation with radiographic findings.颌骨骨坏死中与骨形成相关的标志物及其与影像学表现的相关性。
Oral Maxillofac Surg. 2025 Aug 11;29(1):140. doi: 10.1007/s10006-025-01439-y.
2
A Systematic Review of the Effects of Bisphosphonates on Osteoblasts In Vitro.双膦酸盐对体外成骨细胞作用的系统评价
Calcif Tissue Int. 2025 Jun 16;116(1):86. doi: 10.1007/s00223-025-01390-w.
3
Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs.

本文引用的文献

1
Pain characteristics in medication-related osteonecrosis of the jaws.药物相关性颌骨骨坏死的疼痛特征。
Support Care Cancer. 2021 Feb;29(2):1073-1080. doi: 10.1007/s00520-020-05600-z. Epub 2020 Jun 29.
2
Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.药物相关性颌骨坏死与生活质量:综述与结构化分析
Br J Oral Maxillofac Surg. 2020 Jul;58(6):619-624. doi: 10.1016/j.bjoms.2020.03.010. Epub 2020 Apr 1.
3
General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England.
服用骨稳定药物时关于颌骨坏死的教育和沟通。
Clin Exp Dent Res. 2024 Dec;10(6):e70024. doi: 10.1002/cre2.70024.
4
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.一项基于人群的多中心回顾性研究:乳腺癌患者20年随访期间颌骨药物相关性骨坏死的发病率
J Clin Oncol. 2025 Jan 10;43(2):180-188. doi: 10.1200/JCO.24.00171. Epub 2024 Aug 20.
5
Improvement of Quality of Life after Surgical Treatment of Patients with MRONJ: A Prospective Analysis Using the SF-12 and OHIP-14 Questionnaires.MRONJ患者手术治疗后生活质量的改善:使用SF - 12和OHIP - 14问卷的前瞻性分析
Int J Dent. 2024 Apr 30;2024:4435791. doi: 10.1155/2024/4435791. eCollection 2024.
6
Peri-implantitis increases the risk of medication-related osteonecrosis of the jaws associated with osseointegrated implants in rats treated with zoledronate.种植体周炎增加了接受唑来膦酸盐治疗的大鼠中与骨整合种植体相关的药物相关性颌骨坏死的风险。
Sci Rep. 2024 Jan 5;14(1):627. doi: 10.1038/s41598-023-49647-4.
7
Oral Health-Related Quality of Life and Mental Health Impairment in Patients Affected by Medication-Related Osteonecrosis of the Jaws: A Case-Control Pilot Study.药物性颌骨坏死患者的口腔健康相关生活质量与心理健康损害:一项病例对照试点研究。
Dent J (Basel). 2023 Jun 7;11(6):147. doi: 10.3390/dj11060147.
8
Comparing the Influence of Surgical and Conservative Therapy on Quality of Life in Patients with Early-Stage Medication-Related Osteonecrosis of the Jaw-A Prospective Longitudinal Study.比较手术和保守疗法对早期药物相关性颌骨骨坏死患者生活质量影响的前瞻性纵向研究。
Medicina (Kaunas). 2023 Jan 31;59(2):277. doi: 10.3390/medicina59020277.
9
Oral-Health-Related Quality of Life in Patients with Medication-Related Osteonecrosis of the Jaw: A Prospective Clinical Study.药物相关性颌骨坏死患者的口腔健康相关生活质量:一项前瞻性临床研究。
Int J Environ Res Public Health. 2022 Sep 16;19(18):11709. doi: 10.3390/ijerph191811709.
10
Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw.富血小板纤维蛋白作为药物相关性颌骨坏死患者辅助治疗的非介入性前瞻性观察研究
J Clin Med. 2022 Jan 28;11(3):682. doi: 10.3390/jcm11030682.
全科牙医对通过多学科方法预防药物相关性颌骨骨髓炎 (MRONJ) 来提高患者安全性的看法和态度:英格兰东北部的一项定性研究。
BMJ Open. 2019 Jun 17;9(6):e029951. doi: 10.1136/bmjopen-2019-029951.
4
Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.患者对药物相关性颌骨坏死 (MRONJ)的认知和态度:英格兰的一项定性研究。
BMJ Open. 2019 Mar 3;9(3):e024376. doi: 10.1136/bmjopen-2018-024376.
5
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.药物相关性颌骨坏死:预防、诊断和治疗的定义及最佳实践。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008. Epub 2018 Oct 9.
6
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.《药物相关性颌骨坏死风险患者的口腔管理:初级预防的新模式》。
Biomed Res Int. 2018 Sep 16;2018:2684924. doi: 10.1155/2018/2684924. eCollection 2018.
7
Oral rehabilitation of the cancer patient: A formidable challenge.癌症患者的口腔修复:一项艰巨的挑战。
J Surg Oncol. 2018 Jun;117(8):1729-1735. doi: 10.1002/jso.25075. Epub 2018 May 3.
8
[Oral health-related quality of life in cancer patients].癌症患者的口腔健康相关生活质量
Laryngorhinootologie. 2018 May;97(5):327-333. doi: 10.1055/a-0573-9741. Epub 2018 Mar 1.
9
Impact of Oral Cancer on Quality of Life.口腔癌对生活质量的影响。
Dent Clin North Am. 2018 Jan;62(1):143-154. doi: 10.1016/j.cden.2017.09.001.
10
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.